Expression of the Ets-1 proto-oncogene in melanocytic lesions

Modern Pathology

Volumn 16, Issue 8, 2003, Pages 772-777

  Keehn, Connie A ^a   Smoller, Bruce R ^a   Morgan, Michael B ^a  

^a NONE

Author keywords

Ets 1; Immunohistochemistry; Melanocytic nevi; Melanoma

Indexed keywords

ONCOPROTEIN; TRANSCRIPTION FACTOR ETS 1;

ANALYSIS OF VARIANCE; ANGIOGENESIS; ANTIBODY LABELING; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTIC NEVUS; MELANOMA; MELANOMA IN SITU; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; SCORING SYSTEM; STAINING;

HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-ETS-1; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; SKIN DISEASES; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0042389466     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000082395.59356.4F     Document Type: Article

References (42)

1. Lewin B. Oncogenic conversion by regulatory changes in transcription factors. Cell 1991;64:303-12.
2. Vandenbunder B, Wernert N, Queva C, Desbiens X, Stehelin D. Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion? Folia Biol 1994;40:301-13.
3. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990;1:99-106.
4. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I. Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001;14:415-22.
5. Naito S, Shimizu S, Matsuu M, Nakashima M, Nakayama T, Yamashita S, et al. Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells. Biochem Biophys Res Commun 2002;291:130-8.
6. Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001;194:43-50.
7. Sato Y, Teruyama K, Nakano T, Oda N, Abe M, Tanaka K, et al. Role of transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as endothelial apoptosis. Ann N Y Acad Sci 2001;947:117-23.
8. Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Fagin JA, et al. Expression of Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Am J Pathol 1996;149:1931-9.
9. Tsutsumi S, Kuwano H, Asao T, Nagashima K, Shimura T, Mochiki E. Expression of the Ets-1 angiogenesis-related protein in gastric cancer. Cancer Lett 2000;160:45-50.
10. Ito T, Nakayama T, Ito M, Naito S, Kanematsu T, Sekine I. Expression of ets-1 proto-oncogene in human pancreatic carcinoma. Mod Pathol 1998;11:209-15.
11. Ito Y, Miyoshi E, Takeda T, Sakon M, Tsujimoto M, Yokosaki Y, et al. ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. Oncology 2000;58:248-52.
12. Ito Y, Takeda T, Okada M, Matsuura N. Expression of ets-1 and ets-2 in colonic neoplasms. Anticancer Res 2002;22:1581-4.
13. Sato T, Miwa A. Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. APMIS 2002;110:347-53.
14. Nakayama T, Ito M, Ohtsuru A, Naito S, Sekine I. Expression of the ets-1 proto-oncogene in human colorectal carcinoma. Mod Pathol 2001;14:415-22.
15. Kanda K, Nakayama T, Onizuka S, Tomioka T, Kanematsu T. Expression of the Ets-1 proto-oncogene is linked to cell differentiation of human hepatocellular carcinoma. Hepatogastroenterology 2002;49:747-51.
16. Ozaki I, Mizuta T, Zhao G, Yotsumoto H, Hara T, Kajihara S, et al. Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. Cancer Res 2000;60:6519-25.
17. Saeki H, Kuwano H, Kawaguchi H, Ohno S, Sugimachi K. Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer 2000;89:1670-6.
18. Pande P, Soni S, Kaur J, Agarwal S, Mathur M, Shukla NK, et al. Prognostic factors in betel and tobacco related oral cancer. Oral Oncol 2002;38:491-9.
19. Pande P, Soni S, Chakravarti N, Mathur M, Shukla NK, Ralhan R. Prognostic impact of Ets-1 overexpression in betel and tobacco related oral cancer. Cancer Detect Prev 2001;25:496-501.
20. Pande P, Mathur M, Shukla NK, Ralhan R. Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas. J Pathol 1999;189:40-5.
21. Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 2001;101:242-7.
22. Takanami I, Takeuchi K, Karuke M. Expression of ETS-1 is correlated with urokinase-type plasminogen activator and poor prognosis in pulmonary adenocarcinoma. Tumour Biol 2001;22:205-10.
23. Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Sekine I. Expression of the ets-1 proto-oncogene in human thyroid tumor. Mod Pathol 1999;12:61-8.
24. de Nigris F, Mega T, Berger N, Barone MV, Santoro M, Viglietto G, et al. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res 2001;61:2267-75.
25. Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG, et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 2002;26:539.
26. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, et al. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001;7:551-7.
27. Kitange G, Tsunoda K, Anda T, Nakamura S, Yasunaga A, Naito S, et al. Immunohistochemical expression of Ets-1 transcription factor and the urokinase-type plasminogen activator is correlated with the malignant and invasive potential in meningiomas. Cancer 2000;89:2292-300.
28. Kitange G, Kishikawa M, Nakayama T, Naito S, Iseki M, Shibata S. Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors. Mod Pathol 1999;12:618-26.
29. Naito S, Shimizu K, Nakashima M, Nakayama T, Ito T, Ito M, et al. Overexpression of Ets-1 transcription factor in angiosarcoma of the skin. Pathol Res Pract 2000;196:103-9.
30. Gershtein ES, Medvedeva SV, Babkina W, Kushlinskii NE, Trapeznikov NN. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bull Exp Biol Med 2001;132:670-4.
31. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432-8.
32. Maroulakou IG, Papas TS, Green JE. Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis. Oncogene 1994;9:1551-65.
33. Dhulipal PD. Ets oncogene family. Indian J Exp Biol 1997;35:315-22.
34. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321-5.
35. Wandel E, Grasshoff A, Mittag M, Haustein UF, Saalbach A. Fibroblasts surrounding melanoma express elevated levels of matrix metalloproteinase-1 (MMP-1) and intercellular adhesion molecule-1 (ICAM-1) in vitro. Exp Dermatol 2000;9:34-41.
36. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992;67:331-7.
37. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of endothelial growth factor expression and angiogenesis. Melanoma Res 1997;7 (Suppl 2):S19-26.
38. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas. Am J Pathol 1994;145:510-4.
39. Rongioletti F, Miracco C, Gambini C, Pastorino A, Tosi P, Rebora A. Tumor vascularity as a prognostic indicator in intermediate thickness (0.76-4. 00 mm thick) cutaneous melanoma. A quantitative assay. Am J Dermatopathol 1996;18:474-7.
40. Vlaykova T, Muhonen T, Hahka-Kemppinen M, Pyrhonen S, Jekunen A. Vascularity and prognosis of metastatic melanoma. Int J Cancer 1997;74:326-9.
41. Hudson AR, Smoller BR. Immunohistochemistry in diagnostic dermatopathology. Dermatol Clin 1999;17:667-89.
42. Schach CP, Smoller BR, Hudson AR, Horn TD. Immunohistochemical stains in dermatopathology. J Am Acad Dermatol 2000;43:1094-100.